On July 14, 2020 ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, reported that it hosted a virtual Analyst Day event on Tuesday, July 7th, 2020 (Press release, ImmunSYS, JUL 14, 2020, View Source;utm_medium=rss&utm_campaign=immunsys-announces-it-hosted-a-virtual-analyst-day-event-on-july-7-2020 [SID1234561854]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Eamonn Hobbs, Chairman and CEO of ImmunSYS and Charles J. Link, Jr., M.D., Chief Medical Officer and President of ImmunSYS provided a business overview and highlighted upcoming milestones. Two world-renowned, key opinion leaders, E. David Crawford, M.D. Professor of Urology at the University of San Diego, and Steven J. O’Day, M.D., Executive Director of the John Wayne Cancer Institute and Cancer Clinic provided updates on the current prostate cancer landscape and reviewed new data on the company’s platform technology, YourVaccx. Dr. O’Day provided an in-depth review of the company’s Proof of Concept (PoC) study data that was recently presented at the 2020 AACR (Free AACR Whitepaper) Virtual Annual Meeting II.
A replay of the event can be accessed on the ImmunSYS website in the ‘Publications’ section at www.immunsys.com/publications